Avastin, a drug for Breast Cancer Patients Found Useful but Restricted

Efficacy of a new drug named Avastin to treat tumors from those suffering from breast cancer at their early stages may get revisited. Avastin is found useful in treating breast cancer.

Avastin is found useful in those who were new to cancer, and as doctors expected it has high efficacy of treating breast cancer. Chemotherapy was done in few women with Avastin plus before they go any surgery. Period of surgery arise, doctors didn’t see any sign any of cancer in them. It was a shocking result for everyone as women doing chemotherapy with Avastin plus were safe than those with only chemo alone.

Regular precautions and research are being made as it not stated that Avastin can continue existence. The drug can also cause harm, said experts.

Virginia Commonwealth University, Dr. Harry Bear commented against Avastin as it is not specified yet that it will lead them in success. More researches are going on.

Avastin got sanctioned in the treatment for advanced breast cancer by the United States, in 2008. Researchers found Avastin is helpless in increasing life’s validity, heart problems, bleeding and many other problems can occur. Till November the government retracted the consent.

The California-based Genentech, the Swiss company Roche is the manufacturer of the Avastin. Since in few countries it is not recommended by doctors but in nations like Europe and Japan it is still practiced by the doctors for treating advance breast cancer and the charges is $10,000 a month.

The sponsorships for study included support from drug companies and National Cancer Institute.
Dr. Gary Lyman, who is a researcher at Duke University and one of the members at panel which retracted Avastin, commented on Avastin’s positive side of outcome through study.

Minckwitz suggested in breast cancer patients more important is healing.

Looking at results Lyman stated, it was found nearly 200,000 women in U.S every year detect breast cancer.

Women who underwent with Avastin their sample tissues would be studied for genes bio markers to check which women are positive toward Avastin which will help researchers in finding more improvement in the drug.

Dr. Sandra Horning Global Development Chief of Cancer Drugs for Roche and Genentech said, the company is not planning to alter drug Avastin until more proofs are accessible.

Deep Brain Stimulation for Treating Parkinson’s disease

New study has shown that deep brain stimulation (DBS) can actually improve the life expectancy of patients who are having severe disease like advanced Parkinson’s disease.

Researchers of University of Florida and 14 other medial centers showed the result in the online version of the Lancet Neurology journal. Parkinson’s drugs can have adverse side effects on patients which include tremors, slowness of movement, motor disability to name a few. St. Jude Medical Inc., who has sponsored the test have come up with a DBS device with the help of St. Jude Medical to help reduce the effects of the disease with this device. The research showed that people under the effective symptom control also known as “on time” seems to have a better control over their involuntary movements. Patients who were getting stimulation showed a good increase in their daily work, mobility, emotional well being and physical health.

Dr. Michael S, Okun, first author of the study, administrative director of the UF College of Medicine’s Center for Movement Disorders and Neurorestoration, and the National Medical Director for the National Parkinson Foundation, highlighted that he thinks that with time there will be a lot of improvement in DBS device and was hopeful that lot of patients will get benefits from it.

The procedure is that an electrode is imparted in the brain which is connected to a device, the electrical currents are passed through it and the brain is rectified, the surgeons detects the problem area of the brain and the operation is done according to that. Research, is also going on in Baylor College of Medicine Columbia University, the University of Miami, Texas Health Presbyterian to name a few. Study confirms that the electrical currents given gently to the certain brain type with patients having advanced Parkinson’s disease will improve with time. The improvement in the device and transmittal system will get better.

The use of DBS was approved by FDA way back in 2002. The United States is suffering heavily due to Parkinson’s disease as 500,000 people have Parkinson’s and about 50,000 new cases of disease comes each year, as reported by National Institute of Neurological Disorder and Stroke.

The study has been a wake up call for health organizations and new innovative development in this field as early as possible will only help to deduce the impact of disease that has struck America The infection rate is also come down drastically from 10% to 4% as highlighted by Dr. Gordon H Baltuch, a professor of neurosurgery in the Perelman School of Medicine at the University of Pennsylvania and a study author. Due to research taking place allover the doctor are extremely optimistic about DBS device helping curing the Parkinson’s disease.

Breastfeeding Lowers Risk of Obese Baby

A study revealed the childhood obesity of a child from a diabetic mother that it can be cured when babies are small by breastfeeding them for continuous 6 months.

An experiment was conducted on those 399 of non diabetic and 94 diabetic mothers from the
time they were pregnant, birth and ended at the age of 13 years, said Epidermiologist Tessa Crume, PH.D., MSPH Childhood obesity is analyzed on BMI i.e. body mass index according to the growth of child through breastfeeding.

Dr Crume also highlighted about the time immediately after birth in elaborating the danger of obesity and pregnancy at early stage in toddler life. Women are regularly checked by the doctors, when babies are in mother’s womb the doctors take care of the nutrition level in them and analyze that if it would affect child with obesity.

BMI of infants whose mother is a diabetic patient and fed her child less than six months of time, is BMI recorded slow than those who breast-fed their child full six months.

The Academy of Pediatrics suggested mother’s in order to increase the BMI growth, experts told them to breastfeed their children for regular six months to cut down the chances of childhood obesity and metabolic diseases. Crume explained children who were having chances of getting diabetes or obesity when they were in the womb are more prone to childhood obesity and metabolic disease.

Crume also continued in order to cut down the chances of childhood obesity and to maintain public health Breast-feeding is a must.

The study would encourage the pregnant mother to breastfed their children’s and more importantly to those mother’s who are suffering from diabetes. It is printed in the International Journal of Obesity.
read more at http://www.nature.com/ijo/journal/v28/n10/abs/0802758a.html

GLP-1R Agonists May Help Weight Loss, New Study Reavels

University of Copenhagen scientists have come up with a study that shows Glucagon-like peptide-1 receptor (GLP-1R) agonists can be used to aid in weight loss.

The study was undertaken by university scientists in that adult participants with BODY MASS INDEX (BMI) of 25 or more and not having diabetes mellitus were examined. They were also exposed to drugs like exenatide twice in day and once in a week. Diabetes drugs such as liraglutide were also given daily at clinically applicable doses for the duration of 20 weeks. These drugs that were given to the participants come under the class of GLP-1R agonists. Oral antidiabetic drugs, placebo and insulin are given to the control group.

The study covered broad range of trials, almost 25 of them. The group which was exposed to GLP-IR agonists saw a huge contrast in their weight as compared to the control set of group. Both diabetic and non-diabetic participants showed this effect. The study came out with the conclusion that GLP-1R agonists helps towards improving diastolic, plasma collections of cholesterol, systolic blood pressure a glycaemic regulation. But does not have any effect on plasma concentrations found in liver enzymes.

Scientists also cautioned that GLP-1R agonists have some side-effects like vomiting, nausea and diarrhea. Drug did not develop hypo-glycaemia. So at last the team concluded that GLP-1R if consumed have great effect in attaining weight loss to obese patients having diabetes or not.
The study is available in BRITISH Medical Journal.

For Diet Pills, Drug Companies Want Explicit Approval Rules

Industry experts from U.S see possibility that pharmaceutical companies may halt investing for medicines indicated for the treatment of diseases such as diabetes drugs or weight loss pills.

The reason for that is believed to be lack of precise approval guidelines for medicines. Any product with therapeutic effects has to earn FDA approval before getting in market. Drug manufacturers are confused about how FDA inspects risk factors associated with medicine.

Focus of drug companies is likely to shift to other drugs, such as cancer drugs, where life-saving management is assured in case of severe side effects. The Food and Drug Administration is looking forward to address the concern.

Mr. Christopher Viehbacher, chairman of Pharmaceutical Research and Manufacturers of America (PhRMA), believes that there should be clear methods or guidelines which are being used by FDA so that manufacturer can predict the outcome before investing in production.

Pharma drug companies are preparing strategy for coming Congressional hearing on FDA user fee act. User fee is the fee manufacturer companies pay for faster review of their product by FDA.

Renewal is required from Congress for Prescription Drug User Fee Act (PDUFA) every 5 years. Current fee structure is due to expire on September 2012.

Recently several weight loss pills have been denied approval by Food and Drug Administration. There are many weight loss pills, such as Acomplia. Review panel sensed that obesity drugs by Arena Pharmaceuticals, Orexigen Therapeutics and vivus have approval barrier for diet pills because of safety reasons.

In United States around 70% of the population is over weight and medicines will help weight control along with regime and workouts.

Patient’s well-being and safety are the concern of Food and Drug Department which Mr Viehbacher agrees on.

New Biologic Lipid Lowering Drug To be Used With Statin

A biologic drug found lowering LDL cholesterol when other lipid lowering drug such as statins are not showing adequate result. The drug is in experimental phase and named as REGN727.

The drug is biologic lipid lowering drug class. Researchers reported 75 percent reduction in LDL (bad cholesterol) level when REGN727 administered with statin drug such as Mevacor and generic Lipitor.
The study included 180 patients with LDL level of 100mg/dL. All the participants were given generic lipitor along with REGN727 injection. Result of the study represented at yearly meeting of American College of Cardiology.

40% reduction in LDL level was reported when 50mg of the drug was administered once every 2 weeks. LDL level lowered by 64 percent when dose of the drug raised by 50% i.e. 100mg. 150mg of REGN727 found to be more effective as it reduced LDL by 72 percent.

Reduction was only 5 percent for combination of statin drug and placebo.

Dosage of the drug adjusted to once a month but it does not produce effect as good as once in two week dose, said Dr James McKenney – lead author of the study. Dr McKenney is CEO of National Clinical Research in Richmond.

Working mechanism of new drug is quite different than that of statin drugs (cholesterol lowering drugs). The new drug lowered LDL by preventing action of a protein known as PCSK9.

FDA to take final call on smokeless tobacco products

Dissolvable Tobacco products are restricted for kids below 18 years. Tobacco products may have smell like candy bar but they are not for kids, the United States Food and Drug Department highlighted in a conference this week.

Dissolvable tobacco products are available in market, such as mint flavored, stick and strips of fumeless tobacco. These products are relief to those, to whom smoking is restricted. The desire for nicotine to satisfy ones need, Dissolvable tobacco products are made.

Star Scientific Inc., is promoting two new dissolvable tobacco product, namely Ariva and Stonewall. Even R.J. Reynolds Tobacco Co. is going to promote their Camel Strips,Camel Orbs, and Camel Sticks in 2 towns. Health Supporters are fretful about these Tobacco products, children and teens are more likely to it. The nicotine in product is the reason for addiction.

A pediatrician at Massachusetts General Hospital in Boston, Dr. Jonathan Winickoff commented the products look like a candy although, the nicotine levels in it is the cause of addiction in adolescents and adults.

The smokeless tobacco dissolvable products are second very popular cause of nicotine toxin substance in broods. A study showed in Journal Pediatrics, April 2010.

Winickoff also said that if youth is previously consuming cigarettes then there is not a single question arises that youth is not indulging Dissolvable tobacco products. Parents must bother for their kids and prevent then from consuming those nicotine products. Dissolvable products smell like candy or in mint taste it doesn’t mean that they are harmless, they are equally harmful as cigarettes are.

Headaches, diarrhea, vomiting, nausea are the signs of nicotine symptoms, whereas dangerous nicotine toxic substances leads in heart palpitations, involuntary twitching, muscle paralysis and may even cause deaths.

When experimented, 1 milligram of nicotine given to toddler, diarrhea and vomiting takes place. It is found that Camel Dissolvable Tobacco Products contain 0.6mg to 3.1 mg of nicotine, liable to products. A normal typical cigarette contains 1mg of nicotine.

Orbs manufacturer R.J Reynolds commented that major steps are taking place as to cure unintended breakdown of Camel Dissolvable Tobacco Products in youth, and providing instructions to poison management centers regarding probable consequences of unintended consumption.

Tobacco Products must be out of reach from children below and 18 years, is the warning line written on products.

Food and Drug Administration department has all the power to put control over these products, according to 2009 Family Smoking Prevention and Tobacco Control Act. Winickoff stated that FDA will take major steps in controlling these tobacco products among youth.